PURPOSE: The impact of germline mutations associated with hereditary cancer syndromes in patients on active surveillance (AS) for prostate cancer is poorly defined. We examined the association between family history of prostate cancer (FHP) or family history of cancer (FHC) and risk of progression or adverse pathology at radical prostatectomy (RP) in patients on AS. MATERIALS AND METHODS: Patients on AS at a single tertiary-care center between 2000-2019 were categorized by family history. Disease progression was defined as an increase in Gleason grade on biopsy. Adverse pathology was defined as upgrading/upstaging at RP. Multivariable Cox and logistic regression models were used to assess association between family history and time to progression or adverse pathology, respectively. RESULTS: Among 3,211 evaluable patients, 669 (21%) had FHP, 34 (1%) had FHC and 95 (3%) had both; 753 progressed on AS and 481 underwent RP. FHP was associated with increased risk of progression (HR 1.31; 95% CI, 1.11-1.55; p=0.002) but FHC (HR 0.67; 95% CI, 0.30-1.50; p=0.3) or family history of both (HR 1.22; 95% CI, 0.81-1.85; p=0.3) were not. FHP, FHC or both were not associated with adverse pathology at RP (p >0.4). CONCLUSIONS: While FHP was associated with an increased risk of progression on AS, wide confidence intervals render this outcome of unclear clinical significance. FHC was not associated with risk of progression on AS. In the absence of known genetically defined hereditary cancer syndrome, we suggest FHP and/or FHC should not be used as a sole trigger to preclude patients from enrolling on AS.
PURPOSE: The impact of germline mutations associated with hereditary cancer syndromes in patients on active surveillance (AS) for prostate cancer is poorly defined. We examined the association between family history of prostate cancer (FHP) or family history of cancer (FHC) and risk of progression or adverse pathology at radical prostatectomy (RP) in patients on AS. MATERIALS AND METHODS: Patients on AS at a single tertiary-care center between 2000-2019 were categorized by family history. Disease progression was defined as an increase in Gleason grade on biopsy. Adverse pathology was defined as upgrading/upstaging at RP. Multivariable Cox and logistic regression models were used to assess association between family history and time to progression or adverse pathology, respectively. RESULTS: Among 3,211 evaluable patients, 669 (21%) had FHP, 34 (1%) had FHC and 95 (3%) had both; 753 progressed on AS and 481 underwent RP. FHP was associated with increased risk of progression (HR 1.31; 95% CI, 1.11-1.55; p=0.002) but FHC (HR 0.67; 95% CI, 0.30-1.50; p=0.3) or family history of both (HR 1.22; 95% CI, 0.81-1.85; p=0.3) were not. FHP, FHC or both were not associated with adverse pathology at RP (p >0.4). CONCLUSIONS: While FHP was associated with an increased risk of progression on AS, wide confidence intervals render this outcome of unclear clinical significance. FHC was not associated with risk of progression on AS. In the absence of known genetically defined hereditary cancer syndrome, we suggest FHP and/or FHC should not be used as a sole trigger to preclude patients from enrolling on AS.
Authors: Liana B Guedes; Emmanuel S Antonarakis; Michael T Schweizer; Nooshin Mirkheshti; Fawaz Almutairi; Jong Chul Park; Stephanie Glavaris; Jessica Hicks; Mario A Eisenberger; Angelo M De Marzo; Jonathan I Epstein; William B Isaacs; James R Eshleman; Colin C Pritchard; Tamara L Lotan Journal: Clin Cancer Res Date: 2017-08-08 Impact factor: 12.531
Authors: Marco Randazzo; Alexander Müller; Sigrid Carlsson; Daniel Eberli; Andreas Huber; Rainer Grobholz; Lukas Manka; Ashkan Mortezavi; Tullio Sulser; Franz Recker; Maciej Kwiatkowski Journal: BJU Int Date: 2015-10-06 Impact factor: 5.588
Authors: Piper Nicolosi; Elisa Ledet; Shan Yang; Scott Michalski; Brandy Freschi; Erin O'Leary; Edward D Esplin; Robert L Nussbaum; Oliver Sartor Journal: JAMA Oncol Date: 2019-04-01 Impact factor: 31.777
Authors: Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Elizabeth C Page; Elizabeth K Bancroft; Mark N Brook; Melissa Assel; Mona Hassan Al Battat; Sarah Thomas; Natalie Taylor; Anthony Chamberlain; Jennifer Pope; Holly Ni Raghallaigh; D Gareth Evans; Jeanette Rothwell; Lovise Maehle; Eli Marie Grindedal; Paul James; Lyon Mascarenhas; Joanne McKinley; Lucy Side; Tessy Thomas; Christi van Asperen; Hans Vasen; Lambertus A Kiemeney; Janneke Ringelberg; Thomas Dyrsø Jensen; Palle J S Osther; Brian T Helfand; Elena Genova; Rogier A Oldenburg; Cezary Cybulski; Dominika Wokolorczyk; Kai-Ren Ong; Camilla Huber; Jimmy Lam; Louise Taylor; Monica Salinas; Lidia Feliubadaló; Jan C Oosterwijk; Wendy van Zelst-Stams; Jackie Cook; Derek J Rosario; Susan Domchek; Jacquelyn Powers; Saundra Buys; Karen O'Toole; Margreet G E M Ausems; Rita K Schmutzler; Kerstin Rhiem; Louise Izatt; Vishakha Tripathi; Manuel R Teixeira; Marta Cardoso; William D Foulkes; Armen Aprikian; Heleen van Randeraad; Rosemarie Davidson; Mark Longmuir; Mariëlle W G Ruijs; Apollonia T J M Helderman van den Enden; Muriel Adank; Rachel Williams; Lesley Andrews; Declan G Murphy; Dorothy Halliday; Lisa Walker; Annelie Liljegren; Stefan Carlsson; Ashraf Azzabi; Irene Jobson; Catherine Morton; Kylie Shackleton; Katie Snape; Helen Hanson; Marion Harris; Marc Tischkowitz; Amy Taylor; Judy Kirk; Rachel Susman; Rakefet Chen-Shtoyerman; Allan Spigelman; Nicholas Pachter; Munaza Ahmed; Teresa Ramon Y Cajal; Janez Zgajnar; Carole Brewer; Neus Gadea; Angela F Brady; Theo van Os; David Gallagher; Oskar Johannsson; Alan Donaldson; Julian Barwell; Nicola Nicolai; Eitan Friedman; Elias Obeid; Lynn Greenhalgh; Vedang Murthy; Lucia Copakova; Sibel Saya; John McGrath; Peter Cooke; Karina Rønlund; Kate Richardson; Alex Henderson; Soo H Teo; Banu Arun; Karin Kast; Alexander Dias; Neil K Aaronson; Audrey Ardern-Jones; Chris H Bangma; Elena Castro; David Dearnaley; Diana M Eccles; Karen Tricker; Jorunn Eyfjord; Alison Falconer; Christopher Foster; Henrik Gronberg; Freddie C Hamdy; Vigdis Stefansdottir; Vincent Khoo; Geoffrey J Lindeman; Jan Lubinski; Karol Axcrona; Christos Mikropoulos; Anita Mitra; Clare Moynihan; Gadi Rennert; Mohnish Suri; Penny Wilson; Tim Dudderidge; Judith Offman; Zsofia Kote-Jarai; Andrew Vickers; Hans Lilja; Rosalind A Eeles Journal: Eur Urol Date: 2019-09-16 Impact factor: 20.096
Authors: Yu Jiang; Travis J Meyers; Adaeze A Emeka; Lauren Folgosa Cooley; Phillip R Cooper; Nicola Lancki; Irene Helenowski; Linda Kachuri; Daniel W Lin; Janet L Stanford; Lisa F Newcomb; Suzanne Kolb; Antonio Finelli; Neil E Fleshner; Maria Komisarenko; James A Eastham; Behfar Ehdaie; Nicole Benfante; Christopher J Logothetis; Justin R Gregg; Cherie A Perez; Sergio Garza; Jeri Kim; Leonard S Marks; Merdie Delfin; Danielle Barsa; Danny Vesprini; Laurence H Klotz; Andrew Loblaw; Alexandre Mamedov; S Larry Goldenberg; Celestia S Higano; Maria Spillane; Eugenia Wu; H Ballentine Carter; Christian P Pavlovich; Mufaddal Mamawala; Tricia Landis; Peter R Carroll; June M Chan; Matthew R Cooperberg; Janet E Cowan; Todd M Morgan; Javed Siddiqui; Rabia Martin; Eric A Klein; Karen Brittain; Paige Gotwald; Daniel A Barocas; Jeremiah R Dallmer; Jennifer B Gordetsky; Pam Steele; Shilajit D Kundu; Jazmine Stockdale; Monique J Roobol; Lionne D F Venderbos; Martin G Sanda; Rebecca Arnold; Dattatraya Patil; Christopher P Evans; Marc A Dall'Era; Anjali Vij; Anthony J Costello; Ken Chow; Niall M Corcoran; Soroush Rais-Bahrami; Courtney Phares; Douglas S Scherr; Thomas Flynn; R Jeffrey Karnes; Michael Koch; Courtney Rose Dhondt; Joel B Nelson; Dawn McBride; Michael S Cookson; Kelly L Stratton; Stephen Farriester; Erin Hemken; Walter M Stadler; Tuula Pera; Deimante Banionyte; Fernando J Bianco; Isabel H Lopez; Stacy Loeb; Samir S Taneja; Nataliya Byrne; Christopher L Amling; Ann Martinez; Luc Boileau; Franklin D Gaylis; Jacqueline Petkewicz; Nicholas Kirwen; Brian T Helfand; Jianfeng Xu; Denise M Scholtens; William J Catalona; John S Witte Journal: HGG Adv Date: 2021-11-19
Authors: Tommy Nyberg; Debra Frost; Daniel Barrowdale; D Gareth Evans; Elizabeth Bancroft; Julian Adlard; Munaza Ahmed; Julian Barwell; Angela F Brady; Carole Brewer; Jackie Cook; Rosemarie Davidson; Alan Donaldson; Jacqueline Eason; Helen Gregory; Alex Henderson; Louise Izatt; M John Kennedy; Claire Miller; Patrick J Morrison; Alex Murray; Kai-Ren Ong; Mary Porteous; Caroline Pottinger; Mark T Rogers; Lucy Side; Katie Snape; Lisa Walker; Marc Tischkowitz; Rosalind Eeles; Douglas F Easton; Antonis C Antoniou Journal: Eur Urol Date: 2019-09-06 Impact factor: 20.096
Authors: Kathleen Herkommer; Nikola Maier; Donna P Ankerst; Stefan Schiele; Jürgen E Gschwend; Valentin H Meissner Journal: World J Urol Date: 2020-10-13 Impact factor: 4.226